Cellectis SA (CLLS) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Cellectis SA

NASDAQ | CLLS

1.20

USD

-0.06 (-4.76%)

AT CLOSE (AS OF Apr 3, 2025)

$158M

MARKET CAP

P/E Ratio

-0.41

EPS

$3.4

52 Week High

$1.1

52 Week Low

LIFE SCIENCES

Sector

CLLS Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

CLLS Technicals

Tags:

CLLS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$42M
Total Revenue	$42M
Cost Of Revenue	$0
Costof Goods And Services Sold	$0
Operating Income	-$60M
Selling General And Administrative	$18M
Research And Development	$91M
Operating Expenses	$101M
Investment Income Net	-
Net Interest Income	$3.8M
Interest Income	$11M
Interest Expense	$7.5M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$20M
Income Before Tax	-$37M
Income Tax Expense	-
Interest And Debt Expense	-
Net Income From Continuing Operations	-$37M
Comprehensive Income Net Of Tax	-
Ebit	-$29M
Ebitda	-$9.5M
Net Income	-$37M

Revenue & Profitability

Earnings Performance

CLLS Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$384M
Total Current Assets	$287M
Cash And Cash Equivalents At Carrying Value	$143M
Cash And Short Term Investments	$143M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$96M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$1.1M
Intangible Assets Excluding Goodwill	$1.1M
Goodwill	-
Investments	-
Long Term Investments	$7.5M
Short Term Investments	$117M
Other Current Assets	$3.7M
Other Non Current Assets	-
Total Liabilities	$253M
Total Current Liabilities	$166M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$13M
Total Non Current Liabilities	$86M
Capital Lease Obligations	$43M
Long Term Debt	$44M
Current Long Term Debt	$4.8M
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$91M
Other Current Liabilities	$22M
Other Non Current Liabilities	$882K
Total Shareholder Equity	$131M
Treasury Stock	-
Retained Earnings	-$330M
Common Stock	$5.9M
Common Stock Shares Outstanding	$100M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	$23M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$20M
Capital Expenditures	$3.8M
Change In Receivables	-
Change In Inventory	-
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$89M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	$0
Dividend Payout Common Stock	$0
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$37M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$42M
Total Revenue	$42M
Cost Of Revenue	$0
Costof Goods And Services Sold	$0
Operating Income	-$60M
Selling General And Administrative	$18M
Research And Development	$91M
Operating Expenses	$101M
Investment Income Net	-
Net Interest Income	$3.8M
Interest Income	$11M
Interest Expense	$7.5M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$20M
Income Before Tax	-$37M
Income Tax Expense	-
Interest And Debt Expense	-
Net Income From Continuing Operations	-$37M
Comprehensive Income Net Of Tax	-
Ebit	-$29M
Ebitda	-$9.5M
Net Income	-$37M

CLLS Profile

Cellectis SA Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	9.42%	-	742,693,504
NVDA	$101.80	-7.81%	$2.68T	334,149,797
INTC	$22.43	2.05%	$95.85B	240,924,655
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$5.99	1,796.17%	$26.40M	310,904
MKTW	$9.19	1,684.81%	$19.91M	117,875
PTIX	$0.42	84.14%	$4.04M	177,332,811
MRM	$0.65	74.84%	$2.91M	51,693,935
OSRH	$2.47	68.03%	$40.06M	89,471,971

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

CLLS $1.20 (-4.76%) Quote details